The Pharmacological Management of Osteoporosis

Overview

Journal Mo Med

Specialty General Medicine

Date 2011 May 17

PMID 21568234

Citations 8

Authors

Amy E Riek

Dwight A Towler

Affiliations

Soon will be listed here.

Abstract

Pharmacotherapy is effective in decreasing the incidence of osteoporotic fracture, morbidity, and mortality. This benefit is pronounced in patients at highest risk for fracture: those with prior osteoporotic fracture, very low bone mineral density, or receiving chronic corticosteroid treatment. We review the best pharmacotherapeutic options currently available for treating osteoporosis.

Citing Articles

A Mini Review on Osteoporosis: From Biology to Pharmacological Management of Bone Loss.

Chin K, Ng B, Rostam M, Muhammad Fadzil N, Raman V, Mohamed Yunus F J Clin Med. 2022; 11(21).

PMID: 36362662 PMC: 9657533. DOI: 10.3390/jcm11216434.

Three generations of treatments for osteoporotic vertebral fractures: what is the evidence?.

Nasto L, Jannelli E, Cipolloni V, Piccone L, Cattolico A, Santagada A Orthop Rev (Pavia). 2022; 14(6):38609.

PMID: 36267211 PMC: 9568420. DOI: 10.52965/001c.38609.

A Vitronectin-Derived Peptide Restores Ovariectomy-Induced Bone Loss by Dual Regulation of Bone Remodeling.

Kang H, Park C, Jung S, Jo S, Min B Tissue Eng Regen Med. 2022; 19(6):1359-1376.

PMID: 36207661 PMC: 9679078. DOI: 10.1007/s13770-022-00486-w.

An Up-Date of the Muscle Strengthening Exercise Effectiveness in Postmenopausal Women with Osteoporosis: A Qualitative Systematic Review.

Alonso Perez J, Martin Perez S, Battaglino A, Villafane J, Alonso-Sal A, Sanchez Romero E J Clin Med. 2021; 10(11).

PMID: 34063906 PMC: 8196674. DOI: 10.3390/jcm10112229.

Non-neuronal Role of Acetylcholinesterase in Bone Development and Degeneration.

Luo X, Lauwers M, Layer P, Wen C Front Cell Dev Biol. 2021; 8:620543.

PMID: 33585459 PMC: 7876280. DOI: 10.3389/fcell.2020.620543.

References

Wysowski D . Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360(1):89-90. DOI: 10.1056/NEJMc0808738. View

Kanis J, McCloskey E, Johansson H, Strom O, Borgstrom F, Oden A . How to decide who to treat. Best Pract Res Clin Rheumatol. 2009; 23(6):711-26. DOI: 10.1016/j.berh.2009.09.002. View

Reid I, Miller P, Brown J, Kendler D, Fahrleitner-Pammer A, Valter I . Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010; 25(10):2256-65. DOI: 10.1002/jbmr.149. View

. Drugs for postmenopausal osteoporosis. Treat Guidel Med Lett. 2008; 6(74):67-74. View

Sellmeyer D . Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA. 2010; 304(13):1480-4. DOI: 10.1001/jama.2010.1360. View

Rizzoli R, Yasothan U, Kirkpatrick P . Denosumab. Nat Rev Drug Discov. 2010; 9(8):591-2. DOI: 10.1038/nrd3244. View

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

McDonnell D, Wardell S . The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol. 2010; 10(6):620-8. PMC: 2981619. DOI: 10.1016/j.coph.2010.09.007. View

Rizzoli R, Slosman D, Bonjour J . The role of dual energy X-ray absorptiometry of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis. Am J Med. 1995; 98(2A):33S-36S. DOI: 10.1016/s0002-9343(05)80043-9. View

10.

Perazella M, Markowitz G . Bisphosphonate nephrotoxicity. Kidney Int. 2008; 74(11):1385-93. DOI: 10.1038/ki.2008.356. View

11.

Bachrach L, Ward L . Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2008; 94(2):400-9. DOI: 10.1210/jc.2008-1531. View

12.

Woolf A, Pfleger B . Burden of major musculoskeletal conditions. Bull World Health Organ. 2004; 81(9):646-56. PMC: 2572542. View

13.

Bolland M, Grey A, Gamble G, Reid I . Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010; 95(3):1174-81. DOI: 10.1210/jc.2009-0852. View

14.

Kanis J, McCloskey E, Johansson H, Oden A . Approaches to the targeting of treatment for osteoporosis. Nat Rev Rheumatol. 2009; 5(8):425-31. DOI: 10.1038/nrrheum.2009.139. View

15.

Saag K, Zanchetta J, Devogelaer J, Adler R, Eastell R, See K . Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60(11):3346-55. DOI: 10.1002/art.24879. View

16.

Adams J, Kantorovich V, Wu C, Javanbakht M, Hollis B . Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab. 1999; 84(8):2729-30. DOI: 10.1210/jcem.84.8.5899. View

17.

Mackey D, Lui L, Cawthon P, Bauer D, Nevitt M, Cauley J . High-trauma fractures and low bone mineral density in older women and men. JAMA. 2007; 298(20):2381-8. DOI: 10.1001/jama.298.20.2381. View

18.

Barrett-Connor E, Mosca L, Collins P, Geiger M, Grady D, Kornitzer M . Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355(2):125-37. DOI: 10.1056/NEJMoa062462. View

19.

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View

20.

Kramer I, Keller H, Leupin O, Kneissel M . Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends Endocrinol Metab. 2010; 21(4):237-44. DOI: 10.1016/j.tem.2009.12.002. View